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Influenza remains due to its annual death rate and potential to cause pandemics a 
major public health concern.  Efforts to control the annual spread of influenza have 
centered on prophylactic vaccinations.  Human influenza vaccines are traditionally 
produced in embryonated hen’s eggs.  However, major constraints with this method, 
e.g. allergic reactions induced by egg proteins and lack of scalability have lead to the 
development of cell culture based production processes.  In recent years, several 
continuous cell lines such as the Madin Darby canine kidney (MDCK) or the African 
green monkey kidney Vero cells have been successfully established for the production 
of influenza vaccines in cell culture.  These processes require the modification of 
existing but also the development of new downstream strategies to account for the 
changed upstream technology.  Downstream processing of biological products is 
conventionally subdivided into three steps: capture or concentration, separation or 
fractionation and polishing.  The capture step is commonly the most expensive unit 
operation.  Hence, the efficiency of this step has a large impact on the total process 
economics.   
The presented study focuses on the development of a proficient capture step based on 
lectin-affinity chromatography.  Lectins are a class of carbohydrate specific proteins 
of non-immune origin that have a selective affinity for a carbohydrate or a group of 
carbohydrates.  Immobilized lectins have been used successfully for many years to 
separate and isolate glycoconjugates, polysaccharides, soluble cell components, and 
cells containing glycoproteins with specific carbohydrate structures on its surface.  
The influenza A virus contains two spike glycoproteins on its surface: hemagglutinin 
(HA) and neuraminidase (NA).  HA is the most abundant surface protein.  It is a 
trimeric glycoprotein containing per subunit 3 to 9 N-linked glycosylation sites 
depending on the viral strain.  Here the influenza A/PR/8/34 virus has been selected 
as a model.  The HA molecule of this particular virus contains according to the 
NetNGlyc 1.0 Server prediction six glycosylation sites.  Detailed analysis of these 
sites and their individual glycan structures are presently performed.  Based on 
preliminary structural glycan analysis studies and literature data several HA-binding 
lectins are selected for a pre-screening via lectin-blots.  The most promising lectin-
blot results are obtained from lectins specific for terminal galactose e.g. Erythrina 
cristagalli (ECL), Arachis hypogaea (PNA).  Lectins, by which lectin-blot analysis 
suggests an interaction with viral membrane proteins, are currently screened for their 
suitability as an affinity matrix ligand.  Therefore, centrifuged cultivation broths of 
influenza A/PR/8/34 virus infected MDCK cells are applied to various agarose-
immobilized lectins.  Components interfering with the immobilized lectins are 
selectively adsorbed.  Non or weak binding components are washed from the column.  
Subsequently, bound components are dissociated from the lectin by competitive 
elution with suitable hapten carbohydrates.  This fraction contains the influenza virus 
particles and virally encoded membrane proteins, which have to be further processed 
for vaccine manufacturing.  The extend of the subsequent purification depends on the 
specificity of the lectin binding to virally encoded surface proteins.  Lectins with 
weak or no interaction with host cell proteins or medium components and strong 
interaction with viral membrane glycoproteins represent a powerful tool to 
concentrate and purify viral surface proteins from contaminating nucleic acids, 
medium components, and non-virally encoded host cell proteins.   
